文献速递创伤与烧伤重症综合管理与镇静镇痛

80岁及以上高龄患者肋骨骨折手术稳定固定的结局如何

Surgical stabilization of rib fractures in octogenarians and beyond-what are the outcomes?
PubMed 文献 · J Trauma Acute Care Surg · 2021-01-01
一句话结论多中心回顾性队列研究显示,在80岁及以上严重胸部创伤患者中,肋骨骨折手术稳定固定与死亡率降低独立相关(RR 0.41)。

该多中心回顾性队列研究纳入8个中心2015至2020年接受肋骨骨折手术稳定固定(SSRF)的80岁及以上患者,按中心、年龄、损伤严重度评分和颅内出血情况匹配对照。共纳入360例患者,其中133例(36.9%)接受SSRF。多因素回归显示SSRF组死亡率较非手术组降低(RR 0.41;95%CI 0.24-0.69;P<0.01),但SSRF组肺炎发生率更高、机械通气和ICU停留时间更长。SSRF组出院时使用麻醉药物的可能性更低(RR 0.66;95%CI 0.48-0.90;P=0.01)。早期与晚期SSRF亚组间校正死亡率无差异。作者认为,经仔细选择患者,SSRF或可考虑作为80岁及以上高龄患者的一种可行治疗选择。

要点

  • 在80岁及以上严重胸部创伤患者中,SSRF与非手术管理相比死亡率降低(RR 0.41;95%CI 0.24-0.69;P<0.01)。
  • SSRF组肺炎发生率更高,机械通气时间和ICU停留时间均延长。
  • SSRF组出院时使用麻醉药物的可能性更低(RR 0.66;95%CI 0.48-0.90;P=0.01)。
  • 早期(伤后0-2天)与晚期(伤后3-7天)SSRF亚组的校正死亡率无差异。
  • 接受SSRF的患者损伤严重程度显著高于非手术患者,提示存在选择偏倚。

适用人群与场景

  • 80岁及以上创伤患者,胸部简明损伤定级(AIS)评分≥3分。
  • 排除标准:头部AIS评分>2分、24小时内死亡、希望不升级治疗者。

诊断标准与关键阈值

  • 胸部简明损伤定级(AIS)评分≥3分。
  • 头部简明损伤定级(AIS)评分≤2分。

处置流程与药物剂量

  • SSRF组接受肋骨骨折手术稳定固定;非手术组接受非手术治疗。
  • 亚组分析中,早期SSRF定义为伤后0-2天,晚期SSRF定义为伤后3-7天。

红旗征与不能漏的情况

  • 头部AIS评分>2分的患者被排除,提示严重颅脑损伤者不适合该干预。
  • 24小时内死亡的患者被排除,提示极早期死亡高危者不在研究范围内。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入8个中心2015至2020年360例患者,其中133例(36.9%)接受SSRF。
  • 全样本院内死亡31例(8.6%)。
  • 多因素回归显示,SSRF组较非手术组死亡风险降低(RR 0.41;95%CI 0.24-0.69;P<0.01)。
  • SSRF组肺炎发生率更高,机械通气时间和ICU停留时间均延长。
  • SSRF组出院时使用麻醉药物的可能性更低(RR 0.66;95%CI 0.48-0.90;P=0.01)。
  • 出院目的地无差异。
  • 早期与晚期SSRF亚组间校正死亡率无差异。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 证据等级:治疗性研究,Level IV。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,经仔细选择患者,SSRF或可考虑作为80岁及以上高龄患者的一种可行治疗选择。
  • 接受SSRF的患者损伤更重,且肺炎风险更高、机械通气和ICU停留时间更长,临床决策时需权衡利弊。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Prospective studies of surgical stabilization of rib fractures (SSRF) have excluded elderly patients, and no study has exclusively addressed the ≥80-year-old subgroup. We hypothesized that SSRF is associated with decreased mortality in trauma patients 80 years or older.

METHODS: Multicenter retrospective cohort study involving eight centers. Patients who underwent SSRF from 2015 to 2020 were matched to controls by study center, age, injury severity score, and presence of intracranial hemorrhage. Patients with chest Abbreviated Injury Scale score less than 3, head Abbreviated Injury Scale score greater than 2, death within 24 hours, and desire for no escalation of care were excluded. A subgroup analysis compared early (0-2 days postinjury) to late (3-7 days postinjury) SSRF. Poisson regression accounting for clustered data by center calculated the relative risk (RR) of the primary outcome of mortality for SSRF versus nonoperative management.

RESULTS: Of 360 patients, 133 (36.9%) underwent SSRF. Compared with nonoperative patients, SSRF patients were more severely injured and more likely to receive locoregional analgesia. There were 31 hospital deaths among the entire sample (8.6%). Multivariable regression demonstrated a decreased risk of mortality for the SSRF group, as compared with the nonoperative group (RR, 0.41; 95% confidence interval, 0.24-0.69; p < 0.01). However, SSRF patients were more likely to develop pneumonia, and had an increased duration of both mechanical ventilation and intensive care unit stay. There were no differences in discharge destination, although the SSRF group was less likely to be discharged on narcotics (RR, 0.66; 95% confidence interval, 0.48-0.90; p = 0.01). There was no difference in adjusted mortality between the early and late SSRF subgroups.

CONCLUSION: Patients selected for SSRF were substantially more injured versus those managed nonoperatively. Despite this, SSRF was independently associated with decreased mortality. With careful patient selection, SSRF may be considered a viable treatment option in octogenarian/nonagenarians.

LEVEL OF EVIDENCE: Therapeutic, Level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Pieracci FM, Leasia K, Hernandez MC, et al. Surgical stabilization of rib fractures in octogenarians and beyond-what are the outcomes? J Trauma Acute Care Surg. 2021. PMID: 34016925. doi:10.1097/TA.0000000000003140

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。